Stage I/Smoldering Myeloma
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Additional Evidence Shows Thalomid® Improves Survival in Elderly with Multiple Myeloma
(01/16/2008)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, additional evidence confirms that the addition of Thalomid® (thalidomide) to Alkeran® (melphalan) and prednisone improves survival in elderly patients with multiple myeloma.
Low-dose Steroids Improve Survival in Multiple Myeloma
(12/14/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, use of low doses of the steroid dexamethasone in combination with Revlimid® (lenalidomide) provided significantly improved survival in multiple myeloma compared with higher-doses of the steroid in this treatment combination.
Thalomid®/Alkeran®/Prednisone Named New Standard of Care as Initial Treatment for Elderly Patients with Multiple Myeloma
(10/10/2007)
According to an article recently published in The Lancet, the treatment combination consisting of Thalomid® (thalidomide), Alkeran® (melphalan), and prednisone should be considered the new standard of care for elderly patients with multiple myeloma who have not received previous therapy.
Addition of Thalomid® to VAD-Doxil® Improves Outcomes for Multiple Myeloma
(08/23/2007)
According to an article recently published in the Annals of Oncology, the addition of Thalomid® (thalidomide) to VAD-Doxil (vincristine, liposomal doxorubicin, and dexamethasone) improves progression-free survival compared to VAD-Doxil when used as initial therapy for patients with multiple myeloma.
More...
Stages II-III
Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant
(04/18/2008)
A recently published study indicates that the type of initial chemotherapy for multiple myeloma has no impact on the outcome of patients who later undergo autologous stem cell transplant. These findings appeared in an early online publication of Bone Marrow Transplantation.
Additional Evidence Shows Thalomid® Improves Survival in Elderly with Multiple Myeloma
(01/16/2008)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, additional evidence confirms that the addition of Thalomid® (thalidomide) to Alkeran® (melphalan) and prednisone improves survival in elderly patients with multiple myeloma.
Low-dose Steroids Improve Survival in Multiple Myeloma
(12/14/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, use of low doses of the steroid dexamethasone in combination with Revlimid® (lenalidomide) provided significantly improved survival in multiple myeloma compared with higher-doses of the steroid in this treatment combination.
Thalomid®/Alkeran®/Prednisone Named New Standard of Care as Initial Treatment for Elderly Patients with Multiple Myeloma
(10/10/2007)
According to an article recently published in The Lancet, the treatment combination consisting of Thalomid® (thalidomide), Alkeran® (melphalan), and prednisone should be considered the new standard of care for elderly patients with multiple myeloma who have not received previous therapy.
Velcade® as New Standard of Care for Initial Therapy in Multiple Myeloma
(09/18/2007)
According to results recently published by Millennium Pharmaceuticals, the addition of Velcade® (bortezomib) to the chemotherapy agent Alkeran® (melphalan) and the steroid prednisone significantly improves survival over Alkeran/prednisone only as initial therapy for multiple myeloma.
More...
Recurrent
Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant
(04/18/2008)
A recently published study indicates that the type of initial chemotherapy for multiple myeloma has no impact on the outcome of patients who later undergo autologous stem cell transplant. These findings appeared in an early online publication of Bone Marrow Transplantation.
Revlimid® Improves Survival in Relapsed Multiple Myeloma
(11/26/2007)
According to two articles recently published in the New England Journal of Medicine, Revlimid® (lenalidomide) improves survival for patients with multiple myeloma that has returned following prior therapies.
Velcade® as New Standard of Care for Initial Therapy in Multiple Myeloma
(09/18/2007)
According to results recently published by Millennium Pharmaceuticals, the addition of Velcade® (bortezomib) to the chemotherapy agent Alkeran® (melphalan) and the steroid prednisone significantly improves survival over Alkeran/prednisone only as initial therapy for multiple myeloma.
Velcade® plus Doxil® Approved for Multiple Myeloma
(05/23/2007)
The United States Food and Drug Administration (FDA) recently approved the treatment combination consisting of Velcade® (bortezomib) plus Doxil® (doxorubicin HCl liposome injection) for the treatment of multiple myeloma in patients who have received at least one prior treatment but have not been previously treated with Velcade.
Velcade®, Alkeran®, Prednisone, and Thalomid® Effecive for Relapsed Multiple Myeloma
(03/28/2007)
According to an article recently published in the journal Blood, the treatment regimen referred to as VMPT provides effective therapy for patients with relapsed multiple myeloma.
More...